Oncology

In an ovarian cancer mouse model, the combination therapy group showed an 83% increase in survival duration compared to an untreated group.

The company has initiated the world’s first confirmatory phase 2 trial of a CAR T-cell therapy in solid tumors.

Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed the IND clearance of AVB-001 and the soon-to-initiate phase 1 trial.

The tumor-infiltrating lymphocyte therapy has shown efficacy in the phase 2 C-144-01 trial.

Review top news and interview highlights from the week ending August 26, 2022.

The senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.

Century Therapeutics will initiate the phase 1 ELiPSE-1 study imminently.

The senior vice president of immunology at Cellectis discussed the company’s investigational dual-targeted CAR-T therapy for B-cell malignancies.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

A case study showed that the patient achieved a complete response in 12 months after treatment with CARsgen Therapeutics’ cell therapy.

At a median follow-up of 24 months, the best ORR achieved was 77.6% among 58 evaluable patients with large B-cell lymphoma treated with relma-cel.

Thirty-five patients were previously treated with Innovative Cellular Therapeutics’ GCC19CART in an IRB-approved trial in China.

If approved, the company will initiate the first-in-human STAR-101 phase 1 clinical trial.

Review top news and interview highlights from the week ending August 19, 2022.

The company recently announced a dose escalation in the ACCLAIM-1 study.

Higher doses were associated with improved overall survival, event-free survival, and relapse-free survival.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Tessa Therapeutics presented positive data from the phase 2 CHARIOT study of TT11 in December 2021.

Multiple cell and gene therapy companies have been granted patents for novel technology in 2022.

The novel therapy targets a hormone receptor only expressed at immunologically relevant levels in the ovaries.

A safety review committee approved the dose-escalation after reviewing the first cohort of patients.

The oncologist from Children's Hospital of Philadelphia discussed long-term safety data with tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Review top news and interview highlights from the week ending August 12, 2022.

The FDA recently accepted the company’s BLA for omidubicel for priority review.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.